No

Date

Investors/

Licensee

Service Provide/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

8/1

Sanofi

Arrowhead

Pharmaceuticals

Plozasiran*

APOC3 targeting siRNA

Metabolic

disorder

Severe hypertriglyceridemia

(sHTG)

Registration

395

2

8/6

Kaken

Pharmaceutical

Astria

Therapeutics

Navenibart

mAb inhibitor of KLKB1

Inflammation

Hereditary angioedema

Phase 3

16

3

8/11

Expedition

Therapeutics

Fosun Pharma

XH-S004

DPP-1 inhibitor

Respiratory

diseases

Non-cystic fibrosis bronchiectasis,

COPD

Phase 2

645

4

8/12

Bayer

Kumquat

Biosciences

KQB548

KRAS G12D inhibitor

Oncology

Cancer; Prostate cancer, NSCLC

Preclinical

1,300

5

8/14

Eli Lilly

Superluminal

Medicines

GPCR platform

G protein-coupled receptor

biotech

Cardiometabolic diseases

Cardiometabolic diseases,

Obesity

n/d

1,300

6

8/18

Merch KGaA

Skyhawk

Therapeutics

SkySTAR

RNA splicing platform

Neurology

n/d

n/d

2,000

7

8/18

Boehringer

Ingelheim

Palatin

Technologies

n/d

Melanocortin receptor

agonist

Ophthalmology

Diabetic retinopathy

n/d

327

8

8/19

Halda

Therapeutics

VantAI

Neo-1,
NeoLink

AI and structural

proteomics discovery

platform

Oncology,
Immunology

n/d

n/d

1,000

9

8/19

Santen

Pharmaceutical

RemeGen

RC28-E

VEGF/FGF dual-target

fusion protein

Ophthalmology

Diabetic macular edema(DME),

wet age related macular

degeneration(wAMD)

Phase 3

34.8

10

8/20

Jazz

Pharmaceuticals

Saniona

SAN2355

Selective activator of

Kv7.2/Kv7.3 potassium

channels

Neurology

Epilepsy

Preclinical

42.5

11

8/25

AbbVie

Gilgamesh

Pharmaceuticals

Bretisilocin

5-HT2A receptor agonist

Neurology

Depression

Phase 2

1,200

12

8/26

Novartis

BioArctic

BrainTransporterTM

BBB shuttle platform

Neurology

n/d

n/d

30

13

8/26

Sitala

Fosun Pharma

FXS6837

n/d

Immunology

Autoimmune diseases

Phase 2

670

14

8/28

Novo Nordisk

Replicate

Bioscience

srRNA platform

n/d

Metabolic

disorder

Obesity,

Type 2 Diabetes,

Cardiometabolic diseases

n/d

550

15

8/29

Fosun Pharma

Accro Bioscience

AC-201

TYK2/JAK1 inhibitor

Immunology

Moderate to severe plaque

psoriasis

Phase 1

10.6

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

8/5

SERB Pharmaceuticals

Y-mAbs Therapeutics

Danyelza
(Naxitamab)

αGD2 mAb

Oncology

Relapsed or refractory high-risk neuroblastoma

Marketed

412

2

8/21

Kite Pharma
(Gilead Sciences)

Interius BioTherapeutics

INT2104

In vivo CAR-T/CAR-NK

Oncology

B cell lymphoma

Phase 1

350